Intriguingly, various mouse tumor models showed a dramatic increase in CD8+ TILs after treatment with only trametinib, an inhibitor of mitogen-activated protein kinase kinase (MEK) of the RAS pathway, or in combination with immunotherapy [17,18,19,20,21]. The gene discussed is CD8A; the disease is neoplasm.